Clinical trials: SARS CoV 2 Infection
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-US-O (NCT04426201)
- Testing
- CYT107
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Revimmune
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza health-related outcomes of people with COVID-19 or influenza the effects of vaccines in people with COVID-19 or influenza.
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT06163677
- Testing
- COVID-19 Vaccine
- Sponsor
- Pfizer
Covid-19, Coronavirus Disease 2019
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in…
- Trial name
- NCT04646044
- Testing
- Bempegaldesleukin, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nektar Therapeutics
COVID-19
Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia
Preliminarily investigate the safety and efficacy of two doses of hzVSF-v13 + SOC vs. placebo + SOC for the treatment of COVID-19 pneumonia.
- Trial name
- NCT04676971
- Testing
- hzVSF-v13
- Where
- 9 sites in Italy, Russia
- Volunteers
- 115 people
- Sponsor
- ImmuneMed, Inc.
COVID-19
A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19
This is a Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314.
- Trial name
- NCT05172141
- Testing
- IBI314(low dose), IBI314(high dose), IBI314(medium dose)
- Where
- China
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Multiple Sclerosis
Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.
- Trial name
- NCT05576779
- Testing
- Ofatunumab
- Where
- United States
- Volunteers
- 2,101 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
Wearable Diagnostic for Detection of COVID-19 Infection
The goals of this study are 1) to validate the use of a wearable diagnostic capability and software as a medical device (SaMD) algorithm for the pre or early-symptomatic detection of COVID-19 infection, 2) assess the wearable…
- Trial name
- NCT04742569
- Where
- United States
- Volunteers
- 790 people, healthy volunteers welcome
- Sponsor
- ClinOne, Inc.
Covid-19 Testing
Study Utilizing BIOZEK COVID-19 Antigen Rapid Test
This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test (Saliva) and BIOZEK COVID-19 Antigen Rapid Test (Nasopharyngeal Swab) on samples that are self-collected; and to perform…
- Trial name
- NCT04926779
- Testing
- Biozek Covid-19 Antigen Rapid Test (Saliva)
- Where
- 2 sites in United States
- Volunteers
- 185 people
- Sponsor
- Mach-E B.V.
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
SARS-CoV
Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection
A prospective non-interventional study to evaluate the performance of EASYCOV IVD as point-of-care (POC) test by comparing SARS-CoV-2 positive patients with SARS-CoV-2 negative controls on paired specimens (nasopharyngeal swabs…
- Trial name
- EasyCov (NCT04583319)
- Testing
- EasyCov POC
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Firalis SA
COVID-19
Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations
This is an open, blank controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in the prevention COVID-19 infection among health care workers at high risk of SARS-CoV-2 infection.
- Trial name
- NCT05664919
- Testing
- SA58 Nasal Spray
- Where
- China
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Bioequivalence
Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting…
- Trial name
- Favipiravir (NCT04407000)
- Testing
- Test: Favipiravir 200 mg (LOQULAR), Reference: Favipiravir 200 mg (Avigan)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- World Medicine ILAC SAN. ve TIC. A.S.
Hypertension, Pulmonary, Right Ventricular Overload
The Prevalence of Pulmonary Hypertension in Patients With COVID-19.
The virus infection Covid-19 fills our hospitals and intensive care departments in a very unique way and there is a lack of essential insight into the pathophysiology of the disease.
- Conditions
- Hypertension, Pulmonary, Right Ventricular Overload, COVID
- Trial name
- NCT04459364
- Where
- Sweden
- Volunteers
- 67 people
- Sponsor
- Attgeno AB
COVID-19, SARS-CoV-2 Infection
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Corona Virus Infection
- Trial name
- NCT05037097
- Testing
- ARCT-165, ARCT-154, ARCT-021
- Where
- 4 sites in United States, Singapore and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
COVID-19 Patients
To Evaluate SSD8432/ Ritonavir in Adults With COVID-19
This is a randomized, double-blind, Phase 1b clinical trial to evaluate the safety, Pharmacodynamics, and Pharmacokinetic of SSD8432 combined with ritonavir tablets in adults with COVID-19.
- Trial name
- NCT05369676
- Testing
- SSD8432 dose 1/Ritonavir, SSD8432 dose 2/Ritonavir
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine
This study aims to evaluate the safety and immunogenicity of the preventative vaccine, AdimrSC-2f, in healthy volunteers aged from 20 to 60 years old.
- Trial name
- NCT04522089
- Testing
- AdimrSC-2f
- Where
- Taiwan
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
This study is a randomized, double-blind, placebo-controlled I/II clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation in adults 18…
- Trial name
- NCT04840992
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Pneumonia, COVID-19
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
- Conditions
- Pneumonia, COVID-19, Coronavirus
- Trial name
- FITE19 (NCT04439071)
- Testing
- PTC299, SOC
- Where
- 41 sites in United States, Australia and 9 more
- Volunteers
- 189 people
- Sponsor
- PTC Therapeutics
Covid-19
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19
Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19
- Trial name
- SOC (NCT04440007)
- Testing
- Abivertinib, Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sorrento Therapeutics, Inc.
Viral Pneumonia, Nitric Oxide
Inhaled NO for the Treatment of Viral Pneumonia in Adults
The purpose of this multi center, open label, randomized, study is to obtain information on the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with viral pneumonia
- Conditions
- Viral Pneumonia, Nitric Oxide, Respiratory Disease, Pneumonia, Viral
- Trial name
- NCT04606407
- Testing
- LungFit™
- Where
- 3 sites in Israel
- Volunteers
- 40 people
- Sponsor
- Beyond Air Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.